David E. Martin, PharmD, MBA
Chief Development Officer and Co-Founder, DFH Pharma
Dr. David E. Martin is the co-founder and Chief Development Officer for DFH Pharma, a privately held pharmaceutical company developing second generation maturation inhibitors for the treatment of HIV-1 infection. He has more than 27 years of experience in the Pharmaceutical Industry where has been responsible for managing 24 discovery/early phase clinical programs in a variety of therapeutic areas: cardiovascular, inflammation, respiratory, and HIV.
Dr. Martin was previously SVP for Drug Development & Regulatory Affairs at Tobira Therapeutics, Inc. where he was responsible for all pre-clinical activities, early clinical development, and regulatory affairs. Immediately prior to Tobira, he was SVP for Drug Development & Regulatory Affairs at Panacos Pharmaceuticals where he was part of the team that discovered bevirimat (a first-in-class maturation inhibitor). Dr. Martin has also held positions at DuPont Pharmaceuticals, SmithKline Beecham, PharmaResearch Corporation and Glaxo.
Dr. Martin received his PharmD from the University of Southern California (USC) and completed his Residency in Clinical Pharmacy at the USC School of Pharmacy followed by a Fellowship in Drug Development at The University of North Carolina, Chapel Hill and Glaxo, Inc. He received his Master of Business Administration – Pharmaceutical Marketing from Saint Joseph’s University, Philadelphia, Pennsylvania. Dr. Martin has published more than 137 peer-reviewed, scientific publications and has one granted US patent and 14 provisional patent applications.